Balloon Angioplasty vs. Sirolimus Eluting Stenting in Infrapopliteal Territory

Original Title: Wound Healing Outcomes and Health-Related Quality-of-Life Changes in the ACHILLES Trial1-Year Results From a Prospective Randomized Controlled Trial of Infrapopliteal Balloon Angioplasty Versus Sirolimus-Eluting Stenting in Patients With Ischemic Peripheral Arterial Disease. Reference: Konstantinos Katsanos et al. J Am Coll Cardiol Intv. 2016, online before print.

 

The ACHILLES study (Comparing Angioplasty and DES in the Treatment of Subjects with Ischemic Infrapopliteal Arterial Disease) was a randomized multicenter study comparing balloon angioplasty vs. sirolimus eluting stenting in infrapopliteal territory.

The study had already reported that sirolimus eluting stenting results in lower restenosis and higher event-free survival rates compared to balloon angioplasty.

This sub study assessed wound healing and quality of life in patients with intermittent claudication and critical ischemia due to infrapopliteal lesions.

A total of 200 patients were randomized to balloon angioplasty vs. sirolimus eluting stenting in infrapatellar occlusive lesions. Wound evolution was assessed by photography and quality of life by standardized questions after one year of randomization.

109 open wounds were documented at baseline (54 received sirolimus eluting stents and 55 balloon angioplasty).

At 6 months, wound volume reduction was significantly higher in patients receiving stents (95% reduction with stents vs. 60% reduction with balloons; p=0.048). At one year, complete wound closure rates were also higher in those receiving sirolimus eluting stents (72.9% vs 55.6%; p=0.088).

Quality of life scored (EQ-5D) significantly higher in those receiving stents (p<0.0001) than those receiving balloons.

Conclusion
Sirolimus eluting stenting in infrapopliteal territory accelerates wound healing and could improve quality of life, compared to balloon angioplasty.

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...